Revenue segments as reported by the company.

Software products and services

Drug discovery

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Sales and marketing

General and administrative

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Schrodinger 

Schrödinger, Inc. engages in the provision of chemical simulation software solutions to pharmaceutical industry. It operates through the Software and Drug Discovery business segments. The Software segment sells software to transform drug discovery across the life sciences industry and to customers in materials science industries. The Drug Discovery segment offers diverse portfolio of preclinical and clinical programs, internally and through collaborations, that have advanced to various stages of discovery and development. The company was founded by Richard A. Friesner, William A. Goddard, III and Murco Ringnalda in 1990 and is headquartered in New York, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Schrodinger reports robust revenue growth and eyes strategic expansion

Schrodinger delivered strong financial performance in 2022, driven by revenue growth in software and drug discovery segments.
The company's innovative pipeline advancements and focus on neuroscience therapeutics position it well for future growth.
While facing challenges in operating expenses and revenue projections, Schrodinger has opportunities for expansion through partnerships and customer growth.
Capitalizing on existing strengths and addressing challenges will be key for Schrodinger to sustain its growth trajectory and competitive edge.

Schrodinger (SDGR) reports robust Q1 performance and growth opportunities

Schrodinger (SDGR) had a strong Q1 2023, with revenue growth driven by software and drug discovery collaborations.
The company's balance sheet strengthened, but challenges exist with smaller biopharma revenue mix and customer acquisition.
Opportunities lie in capitalizing on existing customer loyalty, potential revenue growth, and continued investments in technology.
Overall, Schrodinger is well-positioned to leverage its strengths and address challenges to drive future growth.

Schrodinger meets revenue expectations, focuses on AI-driven drug discovery

Schrodinger's Q2 2023 earnings call highlighted solid revenue performance, ongoing software revenue discussions, and investments in R&D for platform development. The company showcased strengths in innovative drug discovery methods, progress on proprietary programs, and FDA clearances. Challenges include revenue fluctuations and uncertainties in revenue projections, while opportunities lie in expanding software contracts and leveraging AI for efficiency.

Schrodinger reports solid Q3 growth amidst expense challenges and opportunities

Schrodinger's Q3 performance showed revenue growth driven by software and drug discovery segments, despite increased expenses.
The company's focus on operational efficiency and proprietary programs positions it well for future growth and market expansion.
While facing challenges in managing expenses and uncertainties in partner priorities, Schrodinger remains committed to innovation and value creation.
Opportunities lie in scaling up software usage, evaluating collaboration programs, and leveraging customer interest for revenue growth.

Schrodinger reports strong revenue growth and strategic collaborations in 2023

Schrodinger's financial performance in 2023 reflects growth in total revenue and software revenue, driven by customer expansions and program advancements.
The company's strengths lie in its strategic focus on global biopharma companies, collaborations for AI tools, and the trend towards hosted contracts.
Challenges include forecasting revenue growth, decision-making on program advancement, and factors influencing software revenue dynamics.
Opportunities exist in the increased demand for computational tools, ongoing discussions for software adoption, and the validation of the platform through collaborations.

Schrodinger reports Q1 revenue growth amidst challenges and collaboration opportunities

Schrodinger's Q1 2024 performance reflects revenue growth driven by software revenue, though challenges in China and decreased gross margin were noted.
The company's strengths lie in regained rights to key inhibitors, promising pipeline advancements, and potential growth in ACV and collaboration opportunities.
While facing challenges in profitability and R&D expenses, Schrodinger is well-positioned to capitalize on opportunities in collaborations, funding, and drug development.
Overall, Schrodinger's strategic focus on innovation, partnerships, and pipeline advancement sets the stage for future growth and market expansion.

Schrodinger reports solid Q2 results, eyes strategic growth opportunities

Schrodinger's Q2 performance reflects steady revenue growth and margin improvement, despite operational challenges.
Strategic partnerships, acquisitions, and innovative solutions position Schrodinger for future expansion and market leadership.
Efforts to control expenses, drive revenue growth, and leverage market opportunities will be crucial for Schrodinger's long-term success.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

NEW YORK--(BUSINESS WIRE)--Schrödinger today announced it will present at Truist Securities Life Sciences AI Symposium - Biotech & Tools.

Schrödinger to Present at Truist Securities Life Sciences AI Symposium - Biotech & Tools

Schrodinger, Inc. (SDGR) CEO Ramy Farid on Q4 2021 Results - Earnings Call Transcript

NEW YORK--(BUSINESS WIRE)--Schrödinger today reported financial results for the fourth quarter and full year 2021.

Schrödinger Reports Financial Results for the Fourth Quarter and Full Year 2021

Schrodinger, Inc. (SDGR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Analysts Estimate Schrodinger, Inc. (SDGR) to Report a Decline in Earnings: What to Look Out for

Harmony Biosciences Holdings

Protagonist Therapeutics

Drug makers with superb pipelines are likely to deliver great returns for long-term investors. Here are three drug stocks to consider.

3 Desirable Drug Stocks With Very Promising Pipelines

NEW YORK--(BUSINESS WIRE)--Schrödinger today announced that it will report Fourth Quarter and Full-Year 2021 Financial Results on February 24, 2022.

Schrödinger to Announce Fourth Quarter and Full-Year 2021 Financial Results on February 24

NEW YORK--(BUSINESS WIRE)--Schrödinger today announced it will present at the SVB Leerink Virtual 11th Annual Global Healthcare Conference.

Schrödinger to Present at SVB Leerink Virtual 11th Annual Global Healthcare Conference

NEW YORK--(BUSINESS WIRE)--Schrödinger today announced the acquisition of XTAL BioStructures, Inc.

Schrödinger Announces Acquisition of XTAL BioStructures, Inc.

SDGR has fallen nearly ~50% since our first publication in May and nearly 70% from its high. However, we believe this drawdown presents the best risk-reward entry since the IPO. The fall has been primarily driven by factors outside the business. Investors in 2021 turned away from biotech, growth, and high multiple stocks, of which SDGR is all three.

Schrödinger: Conviction Remains High, Q4 Report And Guidance Will Be Critical

NEW YORK--(BUSINESS WIRE)--Schrödinger today announced it will present at the H.C. Wainwright BioConnect Conference.

Schrödinger to Present at H.C. Wainwright BioConnect Conference

Apple

Array Technologies

Discovery

Discovery Communications

Dynatrace Inc

Alphabet

II-VI Incorporated

Kaleyra

Microsoft

NVIDIA

STORE Capital

AT&T

AT&T 5.35 % Notes 2017-01.11.66 Global

Tesla

Tis the time of year to turn the page and start fresh. 2021 was not a bad year for my portfolio, but it certainly was not one to brag about. In 2022, my picks are focused on reasonably priced growth with a value stock chaser or two.

Confounded's Top Stock Picks For A Profitable 2022

NEW YORK--(BUSINESS WIRE)--Schrödinger today announced the retirement of chief financial officer Joel Lebowitz.

Schrödinger Announces Retirement of Chief Financial Officer Joel Lebowitz

Embark Technology

vTv Therapeutics

Investing in the most popular stocks on the Street won't make investors rich in a few years. To accomplish that goal, a contrarian spirit is needed.

3 Stocks That Can Make You Rich in Just a Few Years

NEW YORK--(BUSINESS WIRE)--Schrödinger reports preclinical data supporting advancement of its MALT1 Inhibitor Program at American Society of Hematology 2021 Annual Meeting.

Schrödinger Reports Preclinical Data Supporting Advancement Of Its MALT1 Inhibitor Program At American Society Of Hematology 2021 Annual Meeting

After Its Stock Price Doubled Last Year, Why Schrödinger Is Slumping Now

NEW YORK--(BUSINESS WIRE)--Schrödinger today announced it will participate in five upcoming investor conferences.

Schrödinger to Participate in Five Upcoming Investor Conferences

NEW YORK--(BUSINESS WIRE)--Schrödinger today was awarded a grant to accelerate drug discovery in women's health.

Schrödinger Awarded Grant to Accelerate Drug Discovery in Women's Health

The company plunges sharply into the red on the bottom line in its Q3, and misses analyst estimates.

Why Schrödinger Dived by Almost 12% Today

Schrodinger Inc (NASDAQ:SDGR) reported downbeat third-quarter results, mainly due to lower-than-expected drug discovery revenues, according to BofA Securities. The Schrodinger Analyst: Michael Ryskin downgraded Schrodinger from Buy to Neutral and lowered the price target from $80 to $52.

BofA Downgrades Schrodinger On Slower Drug Discovery Ramp

Schrödinger, Inc.'s (SDGR) CEO Ramy Farid on Q3 2021 Results - Earnings Call Transcript

NEW YORK--(BUSINESS WIRE)--Schrödinger today reported financial results for the third quarter of 2021 and provided a company update.

Schrödinger Reports Third Quarter 2021 Financial Results and Provides Company Update

NEW YORK--(BUSINESS WIRE)--Schrödinger today announced it will present new preclinical data from its MALT1 inhibitor program at the ASH 2021 Annual Meeting.

Schrödinger to Present New Preclinical Data From Its MALT1 Inhibitor Program at ASH 2021 Annual Meeting

Earnings Preview: Schrodinger, Inc. (SDGR) Q3 Earnings Expected to Decline

NEW YORK--(BUSINESS WIRE)--Schrödinger today announced that it will report third quarter 2021 financial results on November 10, 2021.

Schrödinger to Host Conference Call to Discuss Third Quarter 2021 Financial Results

Centessa Pharmaceuticals PLC

NEW YORK & BOSTON & LONDON--(BUSINESS WIRE)--Today, Centessa Pharmaceuticals Subsidiary, Orexia Therapeutics, and Schrödinger announced a collaboration to discover novel orexin receptor agonists.

News for Schrodinger Stock (SDGR)